William L. Carroll, MD

  • Specialties: Pediatric Oncology, Pediatric Hematology, Pediatrics
  • Language: English
  • Phone: 212-263-9906

About Me

Conditions and Treatments

childhood cancer, leukemia, lymphoma, blood disorder, anemia, platelet disorders, pancytopenia, stem cell transplantation, acute lymphocytic leukemia (ALL), germ cell tumor, recurrent childhood acute lymphoblastic leukemia, acute myelogenous leukemia (AML)
Show More Conditions


  • Julie and Edward J. Minskoff Professor of Pediatrics, Department of Pediatrics
  • Professor, Department of Pathology
  • Dir Division of Pediatric Hematology/Oncology
  • Assoc Chair Clinical and Translational Research
Board Certifications
  • American Board of Pediatrics (Pediatric Hematology-Oncology), 1987
  • American Board of Pediatrics - Pediatrics, 1984
Education and Training
  • Fellowship, Stanford University Hospital, Hematology Oncology, 1987
  • Fellowship, Stanford University Hospital, Peds Hem/Oncology, 1984
  • Residency, Children's Hospital Medical Center, Pediatrics, 1982
  • MD from University Of California, 1978

Locations and Appointments

62 Insurance Plans Accepted
  • Aetna HMO
  • Aetna Indemnity
  • Aetna Medicare
  • Aetna POS
  • Aetna PPO/EPO
  • Affinity
  • Affinity Exchange- Essential
  • Cigna EPO/POS
  • Cigna PPO
  • ElderPlan
  • Empire Blue Cross Blue Shield EPO
  • Empire Blue Cross Blue Shield HMO
  • Empire Blue Cross Blue Shield Indemnity
  • Empire Blue Cross Blue Shield MediBlue
  • Empire Blue Cross Blue Shield POS
  • Empire Blue Cross Blue Shield PPO
  • Empire Blue Cross Blue Shield Pathways, Enhanced
  • Fidelis Child Health
  • Fidelis Exchange
  • Fidelis Family Health
  • Fidelis Medicaid
  • Fidelis Medicare
  • HIP Access I
  • HIP Access II
  • HIP Child Health
  • HIP Family Health
  • HIP Medicaid
  • HIP Medicare
  • HealthSmart (WTC)
  • Healthfirst
  • Hotel Trades
  • Humana Medicare
  • Local 1199 PPO
  • MagnaCare PPO
  • Medicare
  • MetroPlus Child Health
  • MetroPlus Exchange Plans
  • MetroPlus Family Health
  • MetroPlus Medicaid
  • MetroPlus Medicare
  • MultiPlan/PHCS PPO
  • NY Medicaid
  • NYS Empire Plan
  • Oscar
  • Oxford Exchange
  • Oxford Freedom
  • Oxford Liberty
  • Oxford Medicare
  • UPN Elite
  • UnitedHealthcare Community & State Plan
  • UnitedHealthcare EPO
  • UnitedHealthcare HMO
  • UnitedHealthcare Medicare
  • UnitedHealthcare POS
  • UnitedHealthcare PPO
  • UnitedHealthcare Top Tier
  • Village Caremax
  • Visiting Nurse Service (VNS) Medicare
*Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have been changed.
Stephen D. Hassenfeld Childrens Center for Cancer & Blood Disorders

160 East 32nd Street, 3rd Floor
New York, NY 10016


Phone: 212-263-9906

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

My Research

Our laboratory is focused on two major challenges facing children with acute lymphoblastic leukemia (ALL).

First, in spite of dramatic improvements in outcome one in four children will suffer a relapse and their prognosis is poor.

Second, the "cost" of therapy for those who are cured is high with short and long term side effects. Therefore our laboratory seeks to understand mechanisms of drug resistance and to identify pathways unique to the cancer cell that can serve as targets for more effective, less toxic therapeutic approaches.

In addition we are using genomic and proteomic approaches to predict prognosis better so that therapy can be tailored to the individual patient thereby maximizing chances for cure while minimizing side effects.

We have identified gene expression profiles that predict response to therapy and are validating these signatures in an independent cohort of children currently undergoing therapy for ALL.

In addition similar efforts using expression profiling to characterize blasts at relapse has led to the provisional identification of a number of drug resistance mechanisms in ALL.

We are now using siRNA approaches to validate the functional significance of these pathways and our long term goal is to use relevant pathways as targets for therapy.

Finally we have had a long term interest in defining cell death pathways that operate in vivo and have discovered that leukemic blasts use a variety of pathways to execute apoptosis.

We hypothesize that the route of cell death correlates with response to therapy and such pathways can be modulated to favor cancer cell death thereby maximizing the therapeutic potential of conventional agents.

Our laboratory encompasses the full spectrum of investigation involving basic "bench" research, highly translational efforts using samples from patients and clinical trials in children with ALL.


  • Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group

    Dupuis, L Lee; Lu, Xiaomin; Mitchell, Hannah-Rose; Sung, Lillian; Devidas, Meenakshi; Mattano, Leonard A Jr; Carroll, William L; Winick, Naomi; Hunger, Stephen P; Maloney, Kelly W; Kadan-Lottick, Nina S
    Cancer. 2016 Jan. ?-?

  • Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples

    Lu, Benjamin Y; Thanawala, Shivani U; Zochowski, Kelly C; Burke, Michael J; Carroll, William L; Bhatla, Teena
    Leukemia & lymphoma. 2016 Jan. 1-4

  • Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331

    Mitchell, Hannah-Rose; Lu, Xiaomin; Myers, Regina M; Sung, Lillian; Balsamo, Lyn M; Carroll, William L; Raetz, Elizabeth; Loh, Mignon L; Mattano, Leonard A Jr; Winick, Naomi J; Devidas, Meenakshi; Hunger, Stephen P; Maloney, Kelly; Kadan-Lottick, Nina S
    International journal of cancer. 2016 Jan. 138 (2): 332-339

Read All Publications (186)